Loracarbef

Molecular formula: C16H16CIN3O4 Molecular weight: 349.8 CAS Registry No.: 121961 -22-6 (monohydrate)

SAMPLE Matrix: blood, urine Sample preparation: Plasma or serum. Condition a Sep-Pak C18 SPE cartridge with 2 m l MeOH then 2 mL water, do not allow to go dry. 500 JJLL Plasma or serum + 100 JJLL 100 |xg/mL cephalexin in water + 50 JJLL 25% acetic acid, mix, add to SPE cartridge, wash with two 1 mL portions of water, elute with 3 mL MeOH. Evaporate eluate under nitrogen, add 200 JJLL mobile phase, vortex, inject a 25 |xL aliquot. Urine. Dilute 100:1 (ratio may vary depending on concentration) with water, inject a 50 JiL aliquot. HPLCVARIABLES Column: 150 X 4.6 5 jim Supelcosil LC-18-DB Mobile phase: MeOH:THF:buffer 16:4:80 (Buffer was 1 g sodium 1-heptanesulfonate + 15 mL triethylamine in 1 L water with the pH adjusted to 2.3 with concentrated phosphoric acid.) Column temperature: 30 Flow rate: 1.4 Injection volume: 25-50 Detector: UV 265 CHROMATOGRAM Retention time: 7.5 Internal standard: cephalexin (9.2) Limit of quantitation: 500 ng/mL OTHER SUBSTANCES Extracted: cefaclor, hydroxyloracarbef Noninterfering: acetaminophen, caffeine KEYWORDS plasma; serum; SPE; pharmacokinetics REFERENCE
Kovach, P.M.; Lantz, R.J.; Brier, G. High-performance liquid chromatographic determination of loracarbef, a potential metabolite, cefaclor and cephalexin in human plasma, serum and urine. J.Chromatogr., 1991, 567, 129-139

SAMPLE Matrix: bulk HPLCVARIABLES Column: 250 X 4.6 5 ^m C18 (YMC) Mobile phase: Gradient. A was 6.9 g/L (NH4)H2PO4 adjusted to pH 2.5 with phosphoric acid. B was MeCN: 6.9 g/L (NH4)H2PO4 adjusted to pH 2.5 with phosphoric acid 60:40. A:B from 100:0 to 0:100 over 30 min, maintain at 0:100 for 10 min. Flow rate: 1 Detector: UV 220

CHROMATOGRAM Retention time: 18 OTHER SUBSTANCES Simultaneous: degradation products REFERENCE

Baertschi, S.W.; Dorman, D.E.; Spangle, L.A.; Collins, M.W.; Lorenz, L.J. Formation of fluorescent pyrazine derivatives via a novel degradation pathway of the carbacephalosporin loracarbef. J.Pharm.Biomed.Anal, 1995, 13, 323-328

SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 X 4.6 YMC A303 ODS (YMC) Mobile phase: Gradient. A was 2.4 g/L NaH2PO4 adjusted to pH 2.5 with phosphoric acid. B was MeCN:2.4 g/L NaH2PO4 adjusted to pH 2.5 with phosphoric acid 60:40. A:B from 0:100 to 100:0 over 30 min, maintain at 100:0 for 10 min. Flow rate: 1 Detector: UV 210 CHROMATOGRAM Retention time: 15 OTHER SUBSTANCES Simultaneous: degradation products REFERENCE
Skibic, M.J.; Taylor, K.W.; Occolowitz, J.L.; Collins, M.W.; Paschal, J.W.; Lorenz, L.J.; Spangle, L.A.; Dorman, D.E.; Baertschi, S.W. Aqueous acidic degradation of the carbacephalosporin loracarbef. J.Pharm.ScL, 1993, 82, 1010-1017

SAMPLE Matrix: solutions HPLCVARIABLES Column: 250 X 4.4 Zorbax ODS Mobile phase: MeCN: 25 mM (NH4)H2PO4 10:90 Flow rate: 1 Detector: UV 254 OTHER SUBSTANCES Also analyzed: cefaclor REFERENCE
Pasini, CE.; Indelicato, J.M. Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-l-dethiacephalosporin antibiotic. Pharm.Res., 1992, 9, 250-254